Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02234752 · ClinicalTrials.gov registry record · Phase 2
Galantamine and Memantine Combination for Cognitive Impairments in Schizophrenia
A Phase 2 study, sponsored by Sheppard Pratt Health System.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT02234752 is a Phase 2 study that was terminated before completion, run by Sheppard Pratt Health System. The registered enrollment target is 3 participants.
The verdict
NCT02234752, a Phase 2 study, was terminated before completion, sponsored by Sheppard Pratt Health System.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
Aim: To examine the efficacy of the combination of galantamine and memantine for the treatment of cognitive deficits in outpatients with schizophrenia. Hypothesis: A combination of galantamine and memantine will improve cognitive impairments in patients with schizophrenia. This is an open-label study to evaluate whether a six week course of galantamine ER and memantine XR is effective in improving the cognitive performance of patients with schizophrenia or schizoaffective disorder. The primary outcome measure will be the change in level of cognition as measured by the MATRICS Consensus Cognitive Battery (MCCB). The results of the MATRICS collaborative project recommended the need for standardized cognitive tests that better distinguish the different facets of cognitive dysfunction in schizophrenia. The MCCB will assess the following seven domains: attention/vigilance, reasoning and problem solving, processing speed, social cognition, verbal learning and memory, visual learning and memory, and working memory. The MCCB will be administered at baseline and at the end of the study. We will report total score and each domain score in the MCCB at baseline and six weeks.
Interventions
- DRUG Memantine XR
- DRUG Galantamine ER
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2014-09 |
| Est. Completion | 2016-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02234752
The ClinicalTrials.gov registry entry for NCT02234752 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sheppard Pratt Health System, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Memantine XR is the first listed.
NCT02234752 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02234752 about?
NCT02234752 is a clinical study titled "Galantamine and Memantine Combination for Cognitive Impairments in Schizophrenia". Aim: To examine the efficacy of the combination of galantamine and memantine for the treatment of cognitive deficits in outpatients with schizophrenia. Hypothesis: A combination of galantamine and memantine will improve cognitive impairments in patients with schizophrenia. This is an open-label st...
What is the current status of trial NCT02234752?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2014-09. Estimated completion is 2016-07.
What interventions are being tested in trial NCT02234752?
The interventions under investigation include: Memantine XR (DRUG), Galantamine ER (DRUG).
Who is sponsoring clinical trial NCT02234752?
This trial is sponsored by Sheppard Pratt Health System, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.